Champions Oncology (CSBR)
(Delayed Data from NSDQ)
$6.31 USD
+0.15 (2.44%)
Updated Aug 4, 2025 11:39 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CSBR 6.31 +0.15(2.44%)
Will CSBR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CSBR based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CSBR
Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript
Champions Oncology (CSBR) Trading Resumes After Brief Halt | CSBR Stock News
CSBR Trading Paused Due to Market Volatility | CSBR Stock News
Champions Oncology trading resumes
Champions Oncology trading halted, volatility trading pause